Clinical Trial Update: One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome [Phase 4]

View source ↗

Summary

Phase 4 trial update of oral ziprasidone in metabolic syndrome patients; study terminated with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Disorders with Psychotic Features
• Schizophrenia

Drugs mentioned

• Ziprasidone (ziprasidone)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Schizophrenia and Disorders With Psychotic Features | Phase 4 | Status: TERMINATED | Results posted: 2013-06-19